Home > Cardiology > AHA 2019 > New Approaches to CVD Risk Reduction > Inclisiran safely halves LDL-Cholesterol

Inclisiran safely halves LDL-Cholesterol

Presented By
Prof. R. Scott Wright, Mayo Clinic, Rochester, USA
AHA 2019

Prof. R. Scott Wright (Mayo Clinic, Rochester, USA) presented the latest data from the phase 3, randomised, placebo-controlled, double-blinded ORION-10 trial, testing the effect of the small interfering RNA (siRNA) inclisiran in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated low-density lipoprotein cholesterol (LDL-C) [1]. With a follow-up of 18 months, inclisiran halved LDL-C levels compared with placebo. The safety profile was favourable.

ORION-10 randomised 1,561 ASCVD patients with elevated LDL-C (≥70 mg/mL) who were already taking maximum tolerated statins to receive either 4 injections (at 0, 3, 9, and 15 months) of placebo or of 300 mg inclisiran with a follow-up of 18 months. The co-primary endpoints were percentage of LDL-C change from baseline at day 510 and the average percentage change from day 90 to day 540.

At the study end at day 510, LDL-C was 58...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on